Provided by Tiger Trade Technology Pte. Ltd.

IO Biotech, Inc.

0.7517
+0.05507.89%
Post-market: 0.7283-0.0234-3.11%19:47 EST
Volume:804.66K
Turnover:591.48K
Market Cap:54.08M
PE:-0.56
High:0.7599
Open:0.7135
Low:0.6903
Close:0.6967
52wk High:2.79
52wk Low:0.3234
Shares:71.95M
Float Shares:31.16M
Volume Ratio:0.71
T/O Rate:2.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3356
EPS(LYR):-1.4494
ROE:-240.48%
ROA:-88.58%
PB:59.37
PE(LYR):-0.52

Loading ...

IO Biotech Announces Participation in Upcoming December Investor Conferences

GlobeNewswire
·
Nov 26

IO Biotech Announces Resignation of Chief Accounting Officer

TIPRANKS
·
Nov 22

IO Biotech Appoints CFO Amy Sullivan as Principal Accounting Officer

Reuters
·
Nov 22

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Reuters
·
Nov 20

Piper Sandler Sticks to Its Buy Rating for IO Biotech (IOBT)

TIPRANKS
·
Nov 19

IO Biotech Presents at Jefferies Global Healthcare Conference

TIPRANKS
·
Nov 18

IO Biotech’s Hold Rating Amid Financial and Regulatory Uncertainty

TIPRANKS
·
Nov 16

Analysts Are Neutral on Top Healthcare Stocks: Anavex Life Sciences (AVXL), IO Biotech (IOBT)

TIPRANKS
·
Nov 15

IO Biotech reports $8.4 mln Q3 net loss

Reuters
·
Nov 14

IO Biotech Q3 EPS $(0.13) Beats $(0.34) Estimate

Benzinga
·
Nov 14

IO Biotech Q3 Operating Income USD -19.355 Million

THOMSON REUTERS
·
Nov 14

IO Biotech Q3 Pretax Profit USD -10.042 Million

THOMSON REUTERS
·
Nov 14

IO Biotech Q3 Basic EPS USD -0.13

THOMSON REUTERS
·
Nov 14

Press Release: IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Dow Jones
·
Nov 14

IO Biotech Announces Participation in Upcoming Investor Conferences

GlobeNewswire
·
Nov 12

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire
·
Nov 07

IO Biotech Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Oct 22

Piper Sandler Keeps Their Buy Rating on IO Biotech (IOBT)

TIPRANKS
·
Oct 22

IO Biotech reports expanded Cylembio results

TIPRANKS
·
Oct 20

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

GlobeNewswire
·
Oct 20